Researchers at the University of California, Berkeley, have identified that the mutation to the CCR5 gene that Chinese scientist Jiankui He controversially introduced to two twin babies last year is associated with a 21% increase in mortality in later life.

He claimed to have introduced the delta 32 mutation to the gene in the twin babies because CCR5 is known to facilitate the entry and infection of cells by common human immunodeficiency virus (HIV) strains; the delta 32 mutation interferes with CCR5’s localisation on the surface of the protein for which CCR5 codes. It is believed one twin had one copy of the gene edited, and the other had both copies edited.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

However, since CCR5 is a common protein, “it is likely that a mutation that destroys the protein is, on average, not good for you. Otherwise, evolutionary mechanisms would have destroyed that protein a long time ago,” noted UC Berkeley professor of integrative biology Rasmus Nielsen. This was why Nielsen and his colleague postdoctoral fellow Xinzhu “April” Wei decided to investigate, particularly where the mutation was done to both copies of the CCR5 gene.

Wei added: “Because one gene could affect multiple traits, and because, depending on the environment, the effects of a mutation could be quite different, I think there can be many uncertainties and unknown effects in any germline editing.”

Using data from the BioBank database, which includes medical records from 500,000 UK citizens, the Berkeley scientists identified people with two mutated copies of the CCR5 gene and observed that they had a significantly higher death rate between the ages of 41 and 78 than those with none or one copies of a mutated gene.

They also found fewer people than they expected with the two delta 32 mutated genes in the database, leading Nielsen and Wei to concluded they had died at a higher rate than the general population before their medical records were included in the database.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Nielsen said: “Both the proportions before enrollment and the survivorship after enrollment tell the same story, which is that you have lower survivability or higher mortality if you have two copies of the mutation. There is simply a deficiency of individuals with two copies.”

The Berkeley study builds on previous studies showing that people with two copies of mutated CCR5 genes had a four times higher death risk after influenza infection.

As a result of their findings, Nielsen stated: “Beyond the many ethical issues involved with the CRISPR babies, the fact is that, right now, with current knowledge, it is still very dangerous to try to introduce mutations without knowing the full effect of what those mutations do.

“In this case, it is probably not a mutation that most people would want to have. You are actually, on average, worse off having it.”

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact